Ultragenyx Q2 2024 Earnings Report
Key Takeaways
Ultragenyx reported a strong second quarter in 2024, with total revenue reaching $147 million, a 36% increase compared to the same period in 2023. The company raised its total revenue guidance for 2024 to $530 million to $550 million. Positive data was reported from Phase 1/2, Phase 2/3, and Phase 3 studies.
Total revenue for the second quarter of 2024 was $147 million, a 36% increase year-over-year.
Crysvita revenue for the second quarter of 2024 was $114 million, a 37% increase year-over-year.
Dojolvi revenue for the second quarter of 2024 was $19 million, a 17% increase year-over-year.
Evkeeza revenue for the second quarter of 2024 was $8 million, driven by demand outside the United States.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Forward Guidance
Total revenue guidance increased to be in the range of $530 million to $550 million.
Positive Outlook
- Total revenue guidance increased to be in the range of $530 million to $550 million (previously $500 million to $530 million)
- Crysvita revenue expected to be towards the upper end of the range of $375 million to $400 million.
- Crysvita revenue includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.
- Dojolvi revenue in the range of $75 million to $80 million
- Net Cash Used in Operations less than $400 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income